Palisade Bio details PALI-2108 development for ulcerative colitis at IBD conference

PALISADE BIO, INC.

PALI-2108 is a colon-specific PDE4 inhibitor prodrug for moderate-to-severe ulcerative colitis.
Phase 1 clinical study planned to begin before year-end 2024.
Development supported by $500,000 research agreement with Giiant from the Crohn's & Colitis Foundation.
Presentation given at IBD Innovate in Cambridge, MA on April 9-10, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.